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Cyclin-dependent kinases 7 and 9 specifically regulate
neutrophil transcription and their inhibition drives
apoptosis to promote resolution of inflammation
AE Leitch1, CD Lucas1, JA Marwick1, R Duffin1, C Haslett1 and AG Rossi*,1
Terminally differentiated neutrophils are short-lived but the key effector cells of the innate immune response, and have a
prominent role in the pathogenesis and propagation of many inflammatory diseases. Delayed apoptosis, which is responsible
for their extended longevity, is critically dependent on a balance of intracellular survival versus pro-apoptotic proteins.
Here, we elucidate the mechanism by which the cyclin-dependent kinase (CDK) inhibitor drugs such as R-roscovitine and
DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole) mediate neutrophil apoptosis. We demonstrate (by a combination of
microarray, confocal microscopy, apoptosis assays and western blotting) that the phosphorylation of RNA polymerase II by
CDKs 7 and 9 is inhibited by R-roscovitine and that specific effects on neutrophil transcriptional capacity are responsible for
neutrophil apoptosis. Finally, we show that specific CDK7 and 9 inhibition with DRB drives resolution of neutrophil-dominant
inflammation. Thus, we highlight a novel mechanism that controls both primary human neutrophil transcription and apoptosis
that could be targeted by selective CDK inhibitor drugs to resolve established inflammation.
Cell Death and Differentiation (2012) 19, 1950–1961; doi:10.1038/cdd.2012.80; published online 29 June 2012
Granulocyte apoptosis and their removal by phagocytes,
particularly macrophages, is essential for resolution of
inflammation.1,2 The neutrophil, which although short-lived
in the circulation, is granted an extended life span by survival
signals at inflammatory sites.3 Apoptosis renders these
potentially histotoxic cells functionally redundant4 and
ensures their recognition and clearance by macrophages.2
If this process is uncontrolled, then non-resolving chronic
inflammation results. Neutrophils that are over-activated or
undergo necrosis release their toxic granule contents, causing
unwanted tissue damage. By inducing neutrophil apoptosis
together with efficient macrophage removal, it is possible to
promote the resolution of inflammation.5 Indeed, delivery of
apoptotic cells protects mice from endotoxin-induced shock,5
highlighting a potential therapeutic role for inducing early
apoptosis. Further approaches with equal translational
promise include the use of cyclin-dependent kinase (CDK)
inhibitor drugs,6 aspirin-triggered 15-epi-LXA8 and TRAIL
(via specific death receptor signalling).7,8
To drive neutrophil apoptosis, it is important to understand
the mechanisms responsible for neutrophil survival. A key
neutrophil survival protein is Mcl-1 as demonstrated by
studies using anti-sense Mcl-1 RNA to ‘knockdown’ Mcl-1
andMcl-1 myeloid-specific knockout mice.9,10 Mcl-1 confers a
pro-survival effect by an interaction with pro-apoptotic Bcl-2
homologues (Bid, Bax, Bak) that prevents their association
with the outer mitochondrial membrane and its subsequent
permeabilisation thereby avoiding progression down the
intrinsic apoptotic pathway.11 An important pro-apoptotic
Bcl-2 homologue responsible for regulation of neutrophil
apoptosis, especially in the context of inflammation and
cytokine-mediated extended longevity, is Bim.12 We have
shown that although Mcl-1 is downregulated at the level
of transcription by the CDK inhibitor R-roscovitine protein
levels of Bim are maintained.13 Mcl-1 is an unusually large
Bcl-2 homologue because it contains PEST domains in its
C-terminal tail that target it for degradation by the proteasome11
Rapid up or downregulation of transcription, a short half-life
and extensive regulation, makeMcl-1 an ideal ‘survival switch’
for regulating neutrophil apoptosis. Not only survival signals
(e.g., GM-CSF) but also pharmacological agents (e.g.,
dexamethasone15 and sodium salicylate16) can alter Mcl-1
half-life and neutrophil survival, but there is still a niche
for agents capable of driving resolution of inflammation.
Our work suggests that CDK inhibitor drugs could fill this
niche. R-roscovitine inhibits the activity of the CDKs 2, 5, 7
and 9.14,15 CDKs 2, 7 and 9 all have roles in the regulation of
transcription by the holoenzyme RNApol II.14,15 This effect is
mediated by phosphorylation of the C-terminal domain (CTD)
and is inhibited by R-roscovitine in other cell systems.16 The
transcriptional capabilities of neutrophils have been ques-
tioned; however, key studies have demonstrated that neu-
trophils are transcriptionally active and that this function has
great importance in immune defence.17,18
This manuscript establishes for the first time in primary
human neutrophils that CDK inhibitor-mediated inhibition of
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CDKs 7 and 9 prevents RNApol II phosphorylation leading
to specific effects on transcriptional capacity, promoting
apoptosis.
Results
CDK and protein synthesis inhibitors induce neutrophil
apoptosis. Figure 1 demonstrates the time-course of
neutrophil viability following CDK inhibitor drug treatment
(R-roscovitine, Figures 1a and b; DRB (5,6-dichloro-1-beta-
D-ribofuranosylbenzimidazole), Figure 1b). Effects of CDK
inhibitor drugs were similar to that observed with the
transcription inhibitor actinomycin-D (Figure 1a) and the
translation inhibitor cycloheximide (data not shown).24
R-roscovitine (as we have previously shown7), DRB and
actinomycin-D promote apoptosis as determined by cell
morphology (Figure 1c) and flow cytometry (Figure 1d).
Key regulators of RNApol II-mediated transcription in
neutrophils. Using genechip technology, we identified
CDK gene expression levels in untreated/unstimulated
neutrophils compared with neutrophils stimulated with
LPS (Escherichia coli O127:B8, a bacterial product that
delays neutrophil apoptosis3,25), R-roscovitine or LPS plus
R-roscovitine (Figure 2). The most strongly expressed CDKs
were CDKs 7 and 9 (Figure 2a). Interestingly, LPS stimulated
CDKs 2 and 7 gene expression (Figure 2a) that was inhibited
by 450% by R-roscovitine. The cyclin-binding partners of
CDK7 and 9 (cyclin H and cyclin T1, respectively) were
expressed at higher levels than other cyclins (cyclin D1
shown for comparison; Figure 2b). Cyclin H expression was
negatively regulated by R-roscovitine. MAT1 (me´nage a
trois 1; part of the transcription factor complex IIH (TFIIH) that
contains CDK7) was expressed at low levels and unaffected
by treatment. Endogenous CDK inhibitors, p21 variant (v)1
and p27, were expressed at the gene level and p21v1 was
upregulated by LPS treatment (Figure 2c). By comparison,
p21v2 was only minimally expressed.
Western blotting of neutrophil total lysates was performed
to investigate expression of CDKs at the protein level. We
initially concentrated on CDKs known to be inhibited by
R-roscovitine. CDK5, 7 and 9were highly expressed, whereas
CDK2 appeared to be minimally expressed with only a faint
band observed (Figure 3a). Low levels of CDK2 protein in
human neutrophils were confirmed by comparing lysates with
those prepared form the proliferating cell lines HL-60 and
HepG2 (Figure 3c). Differential nuclear and cytoplasmic lysis
was subsequently performed to investigate the sub-cellular
distribution of CDK proteins (Figure 3b). Antibodies toGAPDH
and histone H3 confirmed differential fractionation, with
GAPDH being exclusively cytoplasmic and a histone H3
complex predominantly expressed in the nuclear fraction.
The minimal CDK2 that was observed appeared to be
preferentially located in the cytoplasmic fraction (Figure 3b).
Figure 1 The CDK inhibitors R-roscovitine and DRB and the transcription inhibitor actinomycin-D drive human neutrophil apoptosis. (a and b) Time-course showing the
change in neutrophil viability (defined as annexin-V-ve/PI-ve) over a 20-h time period in control, R-roscovitine (20 mM), actinomycin-D (10 mM) or DRB (20mM) -treated cells.
(c) Representative cytocentrifuge preparations for examination of morphological changes associated with apoptosis (scale bar 5mm) and (d) representative flow cytometric
analysis of annexin-V binding and PI staining plots at 8 h of culture. Data are representative of n¼ 3 experiments of three separate replicates and are presented as
mean±S.E.M.
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CDK5 was readily detected and was distributed between the
cytoplasmic and nuclear fractions. There appeared to be an
increase in the nuclear fraction of CDK5 on stimulation with
LPS that was blocked by co-treatment with R-roscovitine.
CDK7 was readily detected in both cytoplasmic and nuclear
fractions. Both isoforms (55 and 43 kDa) of CDK9were readily
detected in the neutrophils and appeared equally distributed
between nuclear and cytoplasmic fractions. There was no
obvious effect of LPS stimulation or R-roscovitine treatment
on the distribution or levels of either isoform of CDK9. The
binding partner cyclins of CDKs 7 and 9 (cyclin H and
cyclin T1, respectively) were predominantly expressed in
the nuclear fraction and there was minimal impact of LPS
stimulation or R-roscovitine treatment on this distribution
(Figure 3b).
To further investigate the western blotting observations for
CDK7 and 9, confocal microscopy was performed in both
unstimulated and LPS-stimulated neutrophils (Figures 3d–g).
CDKs 7 and 9 were identified within the nucleus and
cytoplasm by confocal imaging in both conditions that
confirmed our western blotting data.
The CDK inhibitor drug R-roscovitine modulates phos-
phorylation of RNApol II in neutrophils. Recently, it had
become apparent that neutrophils indeed have a capacity for
de novo transcription.17,26,27 The aim of this experiment was
to identify neutrophil transcriptional machinery and to seek
evidence for the involvement of CDKs 7 and 9 in the
regulation of transcription. Phosphorylation of the CTD of
RNApol II, which consists of 52 repeats of heptapeptide Tyr1-
Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (YSPYSPS), provides a
functional assay for CDK7 and 9 activity. CDK7 phosphor-
ylates RNApol II serine 5, whereas CDK9 phosphorylates
predominantly serine 2 (though it can phosphorylate both
under certain conditions in different cell types). In Figure 4,
the total RNA polymerase protein complex and RNA poly-
merase phosphorylated on key serine residues at position 2
(PS2) and 5 (PS5) are identified by western blotting with
densitometry quantification. Phosphorylation on these serine
residues is of known importance to the regulation of transcrip-
tion by CDKs 7 and 9. Significant time-dependent loss of
phosphorylation at serine residues 2 and 5 when neutrophils
were incubated with the CDK inhibitor R-roscovitine is shown
(Figures 4a–c). There was no significant change in total
RNApol II with R-roscovitine treatment (Figure 4d). In addition,
the RNApol II protein was identified in untreated neutrophils
by indirect immunofluorescence detected by confocal micro-
scopy (Figure 4e). It appeared that RNApol II levels were
enhanced following stimulation of neutrophils with LPS,
consistent with enhancement of active gene transcription.
Figure 2 Analysis of CDKs, cyclins and endogenous CDK inhibitors in human neutrophils. Expression levels of human neutrophil CDKs (a), cyclins (b) and endogenous
CDK inhibitors (c) as analysed by Illumina Gene Chip. Neutrophils isolated from four independent donors (n¼ 4) and treated for 4 h with media alone (Control), R-roscovitine
(20mM), LPS (100 ng/ml) or a combination before RNA isolation and interrogation by microarray. Result shows gene expression levels (fluorescence units, f.u.) as
mean±S.E.M. Significant differences Po0.001 between Control and R-roscovitine are shown as *, between LPS and R-roscovitine/LPS as #, and between LPS and control
by þ , analysed using ANOVA with post hoc multivariate analysis by Student’s Newman–Keuls
Figure 3 Human neutrophils express CDKs and their cyclin binding partners. (a) Whole cell or (b) cytoplasmic/nuclear differential lysates prepared after 4 h incubation in
control, R-roscovitine (20 mM), LPS (100 ng/ml) or R-roscovitine and LPS and blotted for CDKs known to be inhibited by R-roscovitine as well as the cyclin binding partners of
CDKs 7 and 9. (c) Low levels of CDK2 in human neutrophils confirmed using the proliferating cell lines HL-60 and HepG2 as a positive control. Densitometry on n¼ 3
presented as mean±S.E.M., analysed using ImageJ software. All gels are representative of at least n¼ 3 experiments. Confocal microscopy in neutrophils either
unstimulated (d and e) or stimulated with LPS (100 ng/ml) (f and g) and probed for CDK7 (d and f) or 9 (e and g) by indirect immunofluorescence. Panels show transmitted
light/bright field (BF), DAPI nuclear staining (blue), and CDK7 or 9 staining (red), final panel shows merged image (MERGE) demonstrating nuclear co-localisation (pink).
Size bar represents 5 mm scale. Leica SP confocal microscope  630 oil immersion. Representative images from at least n¼ 3 experiments
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R-roscovitine affects global gene transcription in LPS-
stimulated and -unstimulated primary human neutro-
phils. In Figure 5, global effects on gene expression for
neutrophils treated with R-roscovitine are illustrated by
representative bar graphs and a heat-map. The heat-map
shows the genes most significantly up and downregulated
across all the four treatment conditions (untreated neutro-
phils (C), R-roscovitine-treated (R), LPS-stimulated (L)
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and LPS/R-roscovitine co-treatment (RL)). In the total of
genes detected, 1656 genes were downregulated, 886
were upregulated and 1359 were not significantly affected
following treatment with R-roscovitine for 4 h. Genes related
to transcription were highly represented in terms of differ-
ential regulation following R-roscovitine treatment. In
Figure 5, the impact on transcription-related genes as well
as data for further gene types of specific interest to this work
(apoptosis, inflammation, cell-cycle) are clearly demon-
strated. The general trend is of gene downregulation
following R-roscovitine treatment. Using gene ontology
cluster analysis (Table 1), it was possible to identify clusters
of genes that are most affected by R-roscovitine treatment.
Differential effect of the CDK inhibitor drug
R-roscovitine on regulators of neutrophil apoptosis.
We hypothesised that if the mechanism of action of
R-roscovitine-driven neutrophil apoptosis was related to an
effect on transcription, it might be prevented or at least
delayed by the stabilisation of Mcl-1. This might have been
achieved by transfection/transduction approaches, but these
techniques have yet to be consistently and reliably applied to
Figure 4 R-roscovitine inhibits RNApol II phosphorylation on serine 2 and serine 5. (a) Western blotting for RNApol II total (Pol tot), phosphorylated on serine 2 (PS2) and
phosphorylated on serine 5 (PS5) after 2 and 4 h in control or R-roscovitine (20 mM) treated neutrophils. Lysates were run on 4% acrylamide gels with blots shown
representative of three experiments. Densitometry (n¼ 3, mean±S.E.M.) for serine 2 (b) and serine 5 (c), normalised to total RNApol II levels (d). Statistical significance
compared to relevant time-point control where Po0.01 is shown as ** and Po0.001 *** by ANOVA with post hoc multivariate analysis by Student’s Newman–Keuls (with a
95% confidence interval). Confocal microscopy of RNApol II (total) in neutrophils either unstimulated (e) or stimulated with LPS (100 ng/ml) (f) by indirect immunofluorescence.
Panels show transmitted light/bright field (BF), DAPI nuclear staining (blue), RNApol II (total) staining (red), final panel shows merged image (MERGE) demonstrating nuclear
colocalisation (pink). Size bar represents 10 mm scale. Leica SP confocal microscope  630 oil immersion. Representative images are shown from n¼ 3 experiments
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primary human neutrophils.28 Therefore co-treatment with a
proteasome inhibitor was utilised. Mcl-1 is an unusual Bcl-2
homologue in that it has a PEST domain that targets it for
degradation in the proteasome in under 2 h.11 Figure 6a
shows that R-roscovitine-mediated loss of neutrophil viability
was reversed at 8 and 12 h with the proteasome inhibitor
MG-132. MG-132 treatment, even in the presence of
R-roscovitine, prevented loss of Mcl-1 protein levels
(Figure 6b). This was in contrast to the use of the caspase
inhibitor z-VAD-fmk that did not prevent R-roscovitine-
induced Mcl-1 downregulation (Figure 6b). Prevention of
neutrophil apoptosis with MG-132 was only evident if MG-
Figure 5 R-roscovitine effects on the neutrophil transcriptome. Neutrophils treated for 4 h with media alone or R-roscovitine (20mM) were subjected to RNA isolation
before interrogation by Illumina Gene Chip microarray. (a) Bar graph shows number of genes down-regulated (42 fold) and up-regulated (42 fold) by R-roscovitine treatment
compared to control. Specific gene families assessed include: (c) transcription, (d) apoptosis, (e) inflammation and (f) cell-cycle. (b) Heat map shows gene expression most
changed (upregulated and downregulated) across the four treatment groups of R-roscovitine (R), R-roscovitine/LPS (RL), Control (C) and LPS alone (L). Neutrophils from 4
donors (n¼ 4)
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132 was administered within 2 h of R-roscovitine treatment
(data not shown), suggesting that Mcl-1 loss was an early
and key event in the induction of apoptosis.
To support the hypothesis that Mcl-1 is essential to neutro-
phil survival and that its downregulation byR-roscovitine leads
to apoptosis, it was important to show that pro-apoptotic bcl-2
Table 1 Gene ontology analysis of neutrophil gene-clusters most affected by R-roscovitine treatment
Downregulated genes (4twofold Po0.01) Upregulated genes (4twofold Po0.01)
1 Positive regulation of I-kappaB kinase/NF-kB cascade Translational elongation
2 Response to unfolded protein Ribosomal small subunit biogenesis
3 Protein transport Immune response
4 Regulation of programmed cell death rRNA processing
5 Regulation of transcription from RNApol II promoter Leukocyte activation during immune response
6 Protein localisation Lysosomal transport
7 Cell cycle Negative regulation of interleukin-8 biosynthetic process
8 mRNA processing Positive regulation of pinocytosis
9 Transcription initiation from RNA polymerase II promoter Defence response to fungus
10 Positive regulation of transcription Leukocyte activation
Illumina Gene Chip technology experiment on n¼4 donors. Over-represented gene ontology terms in genes significantly up and downregulated (up and
downregulation4twofold, R-roscovitine compared to control with significance of Po0.001)
Figure 6 R-roscovitine effects on apoptotic pathways. (a) Neutrophil viability assessed using flow cytometry for annexin-V/PI following culture with media alone (Control),
R-roscovitine (20mM), MG-132 (50mM) or with a combination of R-roscovitine and MG-132. (b) Neutrophils at 5 106/ml in IMDM containing 10% autologous serum were either
lysed immediately (time 0) or incubated in either the absence (control) or presence of R-roscovitine (20mM), MG132 (50mM), zVAD-fmk (100mM) or combinations of these agents
for 2 h, then lysed and immunoblotted for Mcl-1 or b-actin. Blots shown are representative of three experiments. (c and d) Effect of 4 h R-roscovitine (20mM) on gene expression of
bcl-2 homologues (anti-apoptotic (c), pro-apoptotic (d)) measured by Illumina gene chip (n¼ 4 donors). Result shows fold change in gene expression with statistical significance
Po0.001 shown by ***. (e) Mitochondrial membrane integrity analysed by mitocapture dye after 2 h incubation in medium alone (control), R-roscovitine (20mM) alone, MG-132
(50mM) or combined R-roscovitine and MG-132. Mitocapture fluoresces red/orange in the mitochondria of viable neutrophils (Mito intact, solid bars) and green in the cytoplasm
of neutrophils with loss of mitochondrial outer membrane (transmembrane) potential (MOMP, striped bars; fluorescent microscopy  320, scale bar 20mm). (f) Western blotting for
cleaved (active) caspases 9 and 3 after incubation with media alone (c) or R-roscovitine 20mM (R) at the given time points. All experiments (n¼ 3). Statistical significance compared
to relevant time-point control Po0.001 is shown as *** by ANOVA with post hoc multivariate analysis by Student’s Newman–Keuls (with a 95% confidence interval)
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homologues were not downregulated in a similar fashion.
The pro-apoptotic bcl-2 homologue Bim is prominent in
neutrophil apoptosis and is especially relevant to apoptosis
of cytokine-stimulated neutrophils.12 Other bcl-2 homologues
of relevance to neutrophil apoptosis include Bax, Bid and Bad.
We have shown that Bim protein is preserved throughout a
4-h treatment with R-roscovitine.13 At the level of gene
expression, Bim was significantly upregulated, whereas Bax
was significantly downregulated and other pro-apoptotic Bcl-2
homologues remained unaffected (Figure 6d). Pro-survival
Bcl-2 homologues were unaffected at gene expression level,
apart from Mcl-1, which was significantly downregulated
(Figure 6c).
To further assess the relevant apoptotic pathways, we
investigated mitochondrial membrane integrity (Figure 6e).
Mitocapture dye accumulates in mitochondria of viable cells
and fluoresces orange/red, whereas in the apoptotic cells, it
leeches out of permeabilised mitochondria into the cytoplasm
where it fluoresces green. Using this dye, we demonstrated
significant induction of mitochondrial permeabilisation by
R-roscovitine at early time-points where there was no
evidence of morphological changes of apoptosis. Western
blotting for the pro-apoptotic protein Bid revealed no evidence
of cleavage throughout the time-range where apoptosis
occurred (data not shown). R-roscovitine activated the
caspase cascade, with the evidence of caspase-9 and -3
cleavage (activation) by western blotting after 4 h incubation
(Figure 6f).
The CDK inhibitors DRB and R-roscovitine drive resolu-
tion of inflammation in the bleomycin-induced lung
injury model. We investigated the ability of CDK inhibitor
drugs to resolve neutrophilic inflammation associated with
the bleomycin lung injury model (Figure 7a). Bleomycin-
induced lung injury has been a gold standard model for
investigation of lung inflammation and fibrosis with similar
pathology to the human disease idiopathic pulmonary
fibrosis. Mice subjected to bleomycin injury develop signi-
ficant bronchoalveolar lavage (BAL) neutrophilia (Figure 7b)
and a measurable increase in BAL protein (Figure 7d) on
day 7 consistent with inflammatory injury. By contrast, mice
subjected to bleomycin injury, but treated with DRB or
R-roscovitine, have less neutrophils in BAL with no detri-
mental effect on macrophage numbers (Figures 7b and c).
Additionally, there is significantly less protein in BAL of CDK
inhibitor-treated mice compared with vehicle controls
(Figure 7d). There is an apparent trend towards less cell
damage as measured by lactate dehydrogenase release in
BAL of CDK inhibitor-treated mice but this did not reach
statistical significance (Figure 7e). Histological evidence
of neutrophil-dominant inflammation was clear in control
animals at day 7, but in R-roscovitine- or DRB-treated
animals, the inflammation was markedly attenuated with
reductions in inflammatory cell infiltration in the alveoli,
peri-bronchiolar and peri-vascular areas (Figure 7f). This
is in contrast to untreated mice where neutrophils persist
and significant architectural disturbance occurs resulting in
fibrosis. To increase the novelty of this experiment and to
further assess the potential of CDK inhibitor drugs to
translate to clinical therapeutics, it should be noted that we
delivered the CDK inhibitors via the i.t. route to mimic the
delivery of standard inhaled therapies. This allowed us to
decrease the total dose delivered to 10mg/kg (a 10-fold
lower dose than used in our previous study7).
Discussion
Our discovery that CDK inhibitor drugs (specifically
R-roscovitine and DRB) induce neutrophil apoptosis was
unexpected given the cell cycle status of terminally differ-
entiated neutrophils. The only other terminally differentiated
cell type (neurons) studied with these pharmacological agents
demonstrated enhanced longevity.29 Moreover, Klausen
et al.,30 using primary healthy human bone-marrow cells,
described progressive loss of CDKs 2, 4 and 6, which began at
the myelocyte/metamyelocyte stage and was almost com-
plete by full maturation. This coincidedwith upregulation of the
endogenous CDK inhibitor p27kip1. No consistent finding with
regard to the up or downregulation of the CDK-binding
partners, termed cyclins, was obtainable illustrating the
complexity of regulation involved in this system. This finding
was important as other works on granulopoiesis had utilised a
variety of cell lines and discovered several CDK/CDK-binding
partner expression patterns. Interestingly, the endogenous
CDK inhibitor p21 has been described as a novel modulator of
the macrophage response to LPS.31,32 We have demon-
strated functional CDKs, their binding partners and endogen-
ous inhibitors and transcriptional machinery (both at gene and
protein level) and identified specific transcriptional effects of
the CDK inhibitor drugs in neutrophils. Perhaps unsurpris-
ingly, given the terminally differentiated state of these cells,
the most significantly expressed CDKs7,9 have no direct role
in the cell cycle but are essential for transcription of a key
subset of genes.33,34 This correlates well with our finding of a
similarity in the kinetics of apoptosis induced by CDK inhibitor
drugs and the protein transcription inhibitor actinomycin-D
and the protein translation inhibitor cycloheximide.
The standard model of transcription from a promoter
involves the binding and formation of a pre-initiation complex
composed of RNApol II and various TATA box-binding
proteins, kinases and ubiquitin ligases. This RNApol II
holoenzyme is responsible for the majority of RNA transcrip-
tion in mammalian cells. The pre-initiation complex requires
further input before full-length, viable mRNA is produced. In
highly inducible genes such as those involved in inflammatory
signalling or apoptosis, RNApol II recruitment and activation
occur simultaneously. These genes are heavily dependent
on the positive transcription elongation factor b (P-TEFb)
complex. P-TEFb is a heterodimer of CDK9 and cyclin T1
that can phosphorylate serines 2 and 5. Interestingly,
NF-kB-dependent genes are reliant on P-TEFb activity
and there may be a physical interaction between NF-kB
and P-TEFb.35,36 CDK7, cyclin H and the cofactor MAT1
are part of the TFIIH that is important for the initiation of
transcription. LPS stimulation enhances CDK7 gene trans-
cription, suggesting that enhanced transcription directly drives
transcription machinery production (Figure 2a). This process
is downregulated by R-roscovitine. It should be noted that
other proteins have been shown to have an effect on the
phosphorylation status of the CTD of RNApol II including
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CDK1, CDK2, CDK8 and ERK.38 Of these, CDK1 and 8
negatively regulate phosphorylation so their inhibition would
be expected to result in increased phosphorylation and CDK2
has an indirect regulatory effect on CDK7.We have previously
investigated ERK in the context of CDK inhibition and found
no effect on its activity.14 In this manuscript, we show very
minimal CDK2 expression at the protein level and almost none
within the nucleus, so it would seem an unlikely target. Our
work with the CDK7- and 9-specific inhibitor, DRB, also
argues against a significant role for CDK2.
We hypothesised that it was inducible genes (short-lived,
rapidly upregulated, responsive and dependent on CDK
activation) that allow fine control of neutrophil apoptosis
(Figure 6 and Table 1). To support this contention, we have
demonstrated that RNApol II is both present in neutrophils and
phosphorylated by CDKs 7 and 9 to enhance transcriptional
Figure 7 CDK inhibitors R-roscovitine and DRB resolve bleomycin-induced acute lung injury. (a) Schematic of experimental protocol. Analysis of BAL fluid at day 7 for
(b) neutrophil numbers (c) macrophage numbers (d) total protein (e) lactate dehydrogenase. n¼ 5, mean±S.E.M., statistically significant difference compared with vehicle
control shown as **Po0.01 or ***Po0.001 by ANOVA with a Student’s Newman–Keuls multiple comparison post hoc test with a 95% confidence interval. (f) Representative
histological images (stained with haematoxylin and eosin) at magnification  100 (size bar 100mm scale)
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capacity (Figure 4). Inhibition of CDKs 7 and 9 leads to
dephosphorylation of this enzyme and downregulation of
transcription. The transcriptional capacity of neutrophils has
been a matter of some controversy. Work by Cassatella
et al.18 suggested that neutrophils do have the capacity for de
novo transcription.17,26 Here, we describe the machinery by
which they achieve this functionality and a method by which it
may be selectively altered to enhance apoptosis and
resolution of inflammation.
Mcl-1 protein levels are rapidly downregulated by
R-roscovitine before the induction of apoptosis (Figure 6).
Inhibiton of the proteasome by MG-132 prevented both
R-roscovitine-induced Mcl-1 downregulation and apoptosis.
Although caspase inhibition by z-VAD-fmk prevented
neutrophil apoptosis, this did not fully prevent Mcl-1
downregulation, suggesting Mcl-1 downregulation occurs
upstream of caspase activation (Figure 6). It was important
to examine the expression of other pro-apoptotic and anti-
apoptotic bcl-2 homologues to present a comprehensive
picture of apoptosis signalling within the CDK inhibitor-treated
neutrophil. We have previously shown that Bim, a key pro-
apoptotic bcl-2 homologue mediating neutrophil apoptosis, is
maintained at the protein level despite R-roscovitine treat-
ment.13 The Bim knockout mouse phenotype had enhanced
neutrophil survival37 and two recent papers have shown
Bim upregulation in neutrophils in models of inflammation
in vitro and in vivo.12,38 Our data are consistent with a relative
excess of pro-apoptotic bcl-2 homologues occurring following
downregulation of survival proteins (notably Mcl-1) by CDK
inhibitor drugs, the net result being loss of mitochondrial
membrane integrity and apoptosis. Mcl-1 is downregulated at
the gene expression level by R-roscovitine and we hypothe-
sise that this precedes and is responsible for the initiation of
apoptosis as wemeasured changes in the level of this mRNA/
protein at 2 h but detected only a small percentage of
apoptosis by 4 h.
By demonstrating that Mcl-1 is downregulated at the level of
gene expression, we corroborate our finding that direct
inhibition of NF-kB is not responsible for CDK inhibitor-driven
neutrophil apoptosis.13 We hypothesise that a more central,
generalised effect on neutrophil transcription is responsible
for the induction of apoptosis. This effect is particularly evident
in granulocytes because of the importance of the short-lived
protein Mcl-1 to their survival. The imbalance between Mcl-1
and Bim drives neutrophils towards the intrinsic apoptosis
pathway. Neutrophils are extremely sensitive to the changes
in the inflammatory and immunemilieu, and their dependence
on a highly regulated survival protein is an explanation for their
rapid regulation of apoptosis. Our work adds to the literature,
suggesting the fundamental importance of these proteins to
neutrophil survival, and more importantly describes the
fundamental mechanism of action of the CDK inhibitor drugs
in the resolution of inflammation. Finally, we demonstrate the
ability of a CDK7/9-specific pharmacological agent (DRB) to
resolve lung inflammation in a well-characterised in vivo
model.
The work herein provides an insight into the transcriptional
machinery of the neutrophil and demonstrates that CDK
inhibition is an appealing strategy for the manipulation of
this machinery to drive neutrophil apoptosis. Importantly,
we believe our findings will help to advance future trials of
CDK inhibitor drug therapy in the promotion of resolution of
inflammation.
Materials and Methods
Neutrophil isolation and assessment of apoptosis. We isolated
peripheral blood neutrophils from healthy, human volunteers (Lothian Research
Ethics Committee approvals no. 08/S1103/38 or no. 1702/95/4/72) with the use of
dextran sedimentation and Percoll gradients as described,6,19 and cultured the
cells (5 106/ml, 37 oC) in IMDM containing 10% autologous serum. The cells were
incubated with reagents as indicated in the figures either in flat-bottomed 24-well
plates or in 2 ml Eppendorf tubes in a humidified, 37 oC incubator at 5% CO2 or on a
shaking, temperature-controlled heat block. We assessed apoptosis by flow
cytometry with a Coulter FACSCaliber flow cytometer (Beckman-Coulter, Brea,
CA, USA), using annexin-V-conjugated FLUOS (Roche, Welwyn Garden City, UK) in
combination with propidium iodide (PI) (Sigma-Aldrich, Dorset, UK) and used light
microscopy of Diff Quick stained cytocentrifuged preparations to confirm the presence
of morphological changes characteristic of apoptosis. R-roscovitine was obtained
from Calbiochem. 5,6-Dichloro-1-b-D-ribofuranosylbenzimidazole (DRB) and other
chemicals were from Sigma-Aldrich unless stated otherwise.
Western blotting. Cells at a concentration of 5 106/ml per condition were
incubated at 37 oC on a shaking heat block (for times and reagent concentrations
see figure legends). Total cells lysates were prepared at 4 1C as previously
described.13,20 Neutrophils were pelleted by centrifugation at 3000 g for 60 s and
re-suspended either in whole-cell lysis buffer as described (Meijer and Raymond14,
standard lysis) or in 100ml of cytoplasmic lysis buffer (for nuclear/cytoplasmic
differential lysis; AEBSF 0.5 mM, HEPES 50 mM, KCl 50 mM, MgCl2 2 mM, EDTA
0.1 mM, aprotinin 10mg/ml, levamisole 2 mM, leupeptin 10mg/ml, sodium ortho-
vanadate 1 mM, benzamidine 0.5 mM, b-glycerophosphate 10 mM, pepstatin A
10mg/ml, phenanthroline 1 mM, PMSF 1 mM). Sample was incubated on ice for
10 min then 10ml of NP-40 was added, briefly vortexed and centrifuged for 10 min
at 4300 g. Supernatant was removed (the cytoplasmic fraction), and the remaining
cell pellet was re-suspended in 50ml of nuclear lysis buffer (as cytoplasmic plus NaCl
300 mM and glycerol 10%) and placed at 4 oC plus constant shaking for 20 min to
solubilise nuclear proteins. Samples were then centrifuged at 23 100 g for
10 min and supernatant was removed (nuclear fraction). Protein concentration of
lysates were assessed by BCA protein assay (Thermo Scientific, Cramlington, UK)
to ensure equal protein loading and added to an appropriate volume sample buffer
before boiling at 95 oC for 2 min. Lysate were run on 10–12% precast gels
(Thermo Fisher Scientific, Rockford, IL, USA) or on 4% polyacrylamide gels and
transferred onto PVDF (Immobilon-P, Millipore, Herts, UK). Membranes were
blocked for 1 h in 5% (wt/vol) dried milk/TBS/0.1% Tween-20 or 5% BSA TBS/0.1%
Tween-20 (RNAPol II). Membranes incubated at 4 1C overnight with primary
antibodies; Mcl-1 diluted 1 : 500 (mouse monoclonal from R&D, Abingdon, UK and
rabbit polyclonal from Santa Cruz Biotechnology, Santa Cruz, CA, USA); b-actin
diluted 1 : 10 000 (Sigma-Aldrich); CDK2, 5, 7 and 9 and cyclins T1 and H diluted
1 : 500 (Santa Cruz Biotechnology); RNAPol II diluted 1 : 250 (Covance, Princeton,
NJ, USA); GAPDH diluted 1 : 20 000 (Sigma-Aldrich), Histone H3 diluted 1 : 5000
(Abcam, Cambridge, UK). Following 3 5 min washes in TBS/0.1%Tween-20, the
blots were incubated with HRP-conjugated secondary antibody (Dako, Glostrup,
Denmark) diluted 1 : 2500 for 1 h at room temperature before incubation with ECL
reagents (GE Healthcare, Bucks, UK) exposure to BioMax MS-1 x-ray-sensitive film,
and processing (X-Ograph Imaging Systems, Wilts, UK). Densitometry was carried
out using ImageJ software (NIH, Bethesda, MD, USA). Where appropriate HL-60
and HepG2 cell lines were used as positive controls.
Immunofluorescence for neutrophil CDKs 7 and 9 and RNA
pol II. Neutrophils at 2.5 106/ ml were incubated with treatments in 2 ml
Eppendorf tubes on a 37 oC shaking heat block for the indicated time-points and
pelleted by centrifugation at 300 g for 4 min before resuspension and transfer to
coverslips. They were then fixed for 20 min in 3% paraformaldehyde. After
washing and quenching with 50 mM glycine, cells were re-suspended in 50 ml of
10% goat serum (as secondary antibodies were goat) and blocked for 1 h.
Supernatant was removed and coverslips were gently placed onto 100ml of
indicated primary antibody diluted as indicated for 1 h. Following washing, the cells
were incubated with 50ml of appropriate fluorescent-conjugated secondary
antibody as well as nuclear stain (DAPI/PI, 2ml in 1 ml) for 1 h before further
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washing in PBS and finally ddH2O. All experiments included control slides incubated
with no antibody, primary antibody alone or secondary antibody alone. Coverslips were
transferred to slides and mounted with mowiol and nail varnish before visualisation on
confocal microscope (Leica SP5, Leica Microsystems GmbH, Wetzlar, Germany).
Assessment of mitochondrial integrity. MitoCapture (Biovision, Milpitas,
CA, USA) is a fluorescence-based tool for detecting changes in the mitochondrial
transmembrane potential. Neutrophils were isolated as above and incubated with
appropriate reagent at a concentration of 5 104/ml in a flat-bottomed 96-well
plate at 37 oC, 5% CO2 for 2 h. MitoCapture kit used as per manufacturer’s
instructions. Fluorescence microscopy was performed using a Zeiss Axiovert S100
(Zeiss, Oberkochen, Germany) microscope. Cells fluorescing green had lost
mitochondrial membrane potential, whereas those fluorescing orange/red had
intact mitochondria. Three separate experiments with three replicates of individual
treatments were performed. Photographs were made and 500 cells were counted
per replicate.
RNA isolation. Neutrophil purity was confirmed by flow cytometry before RNA
isolation was performed with an initial trizol (Life Technologies, Carlsbad, CA,
USA) extraction stage followed by the use of a Nucleospin RNA II kit (Macherey-
Nagel, Duren, Germany) as per manufacturer’s instructions. RNA was quantified
and assessed with the use of an Agilent Bioanalyser (Santa Clara, CA, USA)
before the gene-chip assay was performed.
Illumina Gene Chip assessment of neutrophil transcriptome.
This was performed by ARK-genomics (Roslin, Midlothian, Scotland, UK) and
subsequent bioinformatics data was generated by Dr. Jon Manning, CIR
Bioinformatics division. Data output by the proprietary Illumina software were
handled using modules of the R-based Bioconductor software suite (http://
www.bioconductor.org). Version 1.14.0 of the ‘lumi’ package formed the core of
the analysis, providing the routines employed to read, adjust background intensity,
transform and normalise the data. The ‘variance stabilising transform’ suggested
by this module’s authors was employed in place of the more conventional log-
transform, before robust spline normalisation. Annotation data were derived initially
from an Illumina-provided annotation file, with complementary information taken
from the chip-specific ‘illuminaHumanv3’ and more generic ‘lumiHumanAll’
Bioconductor annotation packages. The level and significance of differential
expression for each probe was assessed by use of linear models and empirical
Bayes from the ‘Limma’ package and the resulting P values were adjusted for
multiple testing by use of the Benjamini–Hochberg method. Fold changes were
derived with the aid the ‘gtools’ package. Processed data were stored in a
relational database with a dynamic front-end for further analysis.21–23
Administration of bleomycin sulphate and CDK inhibitor drugs.
Female C57BL/6J mice weighing a minimum of 20 g were used for all
experiments. The mice were briefly anesthetised using Isofluorane and bleomycin
sulphate (0.033 mg; Apollo Scientific, Cheshire, UK) administered to the lungs via
the trachea (i.t.), in a volume of 50ml. On day 2 and 5 post-bleomycin
administration, mice (6 per group) were treated i.t. with either 50 ml of 0.05%
DMSO vehicle control or 10 mg/kg of R-roscovitine or DRB.
BAL and histology. Mice were killed 7 days after bleomycin or saline
administration with a single 200 ml intraperitoneal injection of sodium pentobarbi-
tone (200 mg/ml). The lungs were cannulated via the trachea in situ using a fine
cannula that was tied in place with a single suture and BAL was performed using
three sequential washes of 0.8 ml ice-cold sterile 0.9% saline. All samples were
centrifuged at 180 g for 5 min at 4 1C, the supernatants removed and the cell
pellets resuspended in 0.5 ml sterile 0.9% saline. Total cell numbers were counted
using a nucleocounter and cytocentrifuge smears prepared and stained with Diff
Quick for differential cell-counts to be made. At least 300 cells per slide were
counted and the results expressed as total number of neutrophils and
macrophages in the lung lavage. Histological analysis of the 7 day experiments
(3 mice per group) was undertaken without BAL to maintain tissue integrity and
lung injury was assessed by histological examination of paraffin-embedded lung
sections stained with hematoxylin and eosin.
Statistical analyses (excluding illumina data, see above). All
experiments were performed at least three times unless stated otherwise and each
treatment done in triplicate and the results are expressed as the mean±S.E.M.
Data were analysed by an one-way ANOVA with a Student’s Newman–Keuls
multiple comparison post hoc test with a 95% confidence interval (InStat software,
Graphpad Software Inc., La Jolla, CA, USA).
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